|
1.
Borchers AT, Naguwa SM, Keen CL, Gershwin ME.
Immunopathogenesis of Sjogren's syndrome. Clin Rev Allergy
Immunol. 2003;25:89-104.
https://doi.org/10.1385/CRIAI:25:1:89
PMid:12794264
|
|
|
|
2.
Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of
muscarinic receptor autoantibodies on parasympathetic
neurotransmission in Sjogren's syndrome. Arthritis Rheum.
2000;43:1647-54.
https://doi.org/10.1002/1529-0131(200007)43:7<1647::AID-ANR31>3.0.CO;2-P
PMid:10902771
|
|
|
|
|
3.
Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology
(Oxford). 2006;45:iii3-4.
https://doi.org/10.1093/rheumatology/kel282
PMid:16987829
|
|
|
|
|
4.
Harley J, Scofield R, Reichlin M. Anti-Ro in Sjogren's syndrome
and systemic lupus erythematosus. Rheumatic
diseases clinics of North America. 1992;18:337-58.
PMid:1626073
|
|
|
|
|
5.
Shearn MA. Sjögren's syndrome in association with scleroderma. Annals
of internal medicine. 1960;52:1352-62.
https://doi.org/10.7326/0003-4819-52-6-1352
PMid:14445694
|
|
|
|
|
6.
Kassan SS, Moutsopoulos HM. Clinical manifestations and early
diagnosis of Sjogren syndrome. Archives of
internal medicine. 2004;164:1275-84.
https://doi.org/10.1001/archinte.164.12.1275
PMid:15226160
|
|
|
|
|
7.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA
statement. BMJ. 2009;339:b2535.
PMid:19622551 PMCid:PMC2714657
|
|
|
|
|
8.
Ramos-Casals M, Loustaud-Ratti V, De Vita S, Zeher M, Bosch
J-A, Toussirot E, et al. Sjögren syndrome associated with
hepatitis C virus: a multicenter analysis of 137 cases. Medicine.
2005;84:81-9.
https://doi.org/10.1097/01.md.0000157397.30055.c9
PMid:15758837
|
|
|
|
|
9.
Bell M, Askari A, Bookman A, Frydrych S, Lamont J, McComb J, et
al. Sjogren's syndrome: a critical review of clinical
management. The Journal of rheumatology. 1999;26:2051-61.
PMid:10493692
|
|
|
|
|
10.
Carsons S. A review and update of Sjogren's syndrome: manifestations,
diagnosis, and treatment. The American journal of
managed care. 2001;7:S433-43.
PMid:11605978
|
|
|
|
|
11.
Tishler M, Barak Y, Paran D, Yaron M. Sleep disturbances,
fibromyalgia and primary Sjogren's syndrome. Clin
Exp Rheumatol. 1997;15:71-4.
PMid:9093776
|
|
|
|
|
12.
Kang HI, Fei HM, Saito I, Sawada S, Chen SL, Yi D, et al.
Comparison of HLA class II genes in Caucasoid, Chinese, and
Japanese patients with primary Sjogren's syndrome. J
Immunol. 1993;150:3615-23.
PMid:8468491
|
|
|
|
|
13. Miyagawa S, Shinohara K,
Nakajima M, Kidoguchi K, Fujita T, Fukumoto T, et al. Polymorphisms of HLA class II genes
and autoimmune responses to Ro/SS-A-La/SS-B among Japanese
subjects. Arthritis Rheum. 1998;41:927-34.
https://doi.org/10.1002/1529-0131(199805)41:5<927::AID-ART21>3.0.CO;2-R
PMid:9588746
|
|
|
|
|
14.
Jonsson R, Moen K, Vestrheim D, Szodoray P. Current issues in
Sjogren's syndrome. Oral diseases. 2002;8:130-40.
https://doi.org/10.1034/j.1601-0825.2002.02846.x
PMid:12108757
|
|
|
|
|
15.
Pflugfelder SC, Crouse CA, Monroy D, Yen M, Rowe M, Atherton
SS. Epstein-Barr virus and the lacrimal gland pathology of
Sjogren's syndrome. Am J Pathol. 1993;143:49-64.
PMid:8391219 PMCid:PMC1886957
|
|
|
|
|
16.
Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling
Sjogren's syndrome in HTLV-1 tax transgenic mice. Nature.
1989;341:72-4.
https://doi.org/10.1038/341072a0
PMid:2788824
|
|
|
|
|
17.
Shim GJ, Warner M, Kim HJ, Andersson S, Liu L, Ekman J, et al.
Aromatase-deficient mice spontaneously develop a
lymphoproliferative autoimmune disease resembling Sjogren's
syndrome. Proc Natl Acad Sci U S A. 2004;101:12628-33.
https://doi.org/10.1073/pnas.0405099101
PMid:15314222 PMCid:PMC515108
|
|
|
|
|
18.
Ishimaru N, Arakaki R, Yoshida S, Yamada A, Noji S, Hayashi Y.
Expression of the retinoblastoma protein RbAp48 in exocrine
glands leads to Sjogren's syndrome-like autoimmune exocrinopathy.
J Exp Med. 2008;205:2915-27.
https://doi.org/10.1084/jem.20080174
PMid:19015307 PMCid:PMC2585852
|
|
|
|
|
19.
Valtysdottir ST, Wide L, Hallgren R. Mental wellbeing and
quality of sexual life in women with primary Sjogren's syndrome
are related to circulating dehydroepiandrosterone sulphate. Ann
Rheum Dis. 2003;62:875-9.
https://doi.org/10.1136/ard.62.9.875
PMid:12922962 PMCid:PMC1754646
|
|
|
|
|
20.
Brennan MT, Sankar V, Leakan RA, Grisius MM, Collins MT, Fox
PC, et al. Sex steroid hormones in primary Sjogren's syndrome.
J Rheumatol. 2003;30:1267-71.
PMid:12784401
|
|
|
|
|
21.
Sullivan DA, Belanger A, Cermak JM, Berube R, Papas AS,
Sullivan RM, et al. Are women with Sjogren's syndrome
androgen-deficient? J Rheumatol. 2003;30:2413-9.
PMid:14677186
|
|
|
|
|
22.
Taiym S, Haghighat N, Al-Hashimi I. A comparison of the hormone
levels in patients with Sjogren's syndrome and healthy
controls. Oral surgery, oral medicine, oral pathology, oral
radiology, and endodontics. 2004;97:579-83.
https://doi.org/10.1016/j.tripleo.2003.10.033
PMid:15153869
|
|
|
|
|
23.
Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the
initiation and perpetuation of Sjogren's syndrome. Nat
Rev Rheumatol. 2010;6:529-37.
https://doi.org/10.1038/nrrheum.2010.118
PMid:20683439
|
|
|
|
|
24. Spachidou MP, Bourazopoulou E,
Maratheftis CI, Kapsogeorgou EK, Moutsopoulos HM, Tzioufas AG,
et al. Expression
of functional Toll-like receptors by salivary gland epithelial
cells: increased mRNA expression in cells derived from patients
with primary Sjogren's syndrome. Clin Exp Immunol. 2007;147:497-503.
https://doi.org/10.1111/j.1365-2249.2006.03311.x
PMid:17302899 PMCid:PMC1810489
|
|
|
|
|
25.
Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI.
Gene expression profiling of minor salivary glands clearly
distinguishes primary Sjogren's syndrome patients from healthy
control subjects. Arthritis Rheum. 2005;52:1534-44.
https://doi.org/10.1002/art.21006
PMid:15880807
|
|
|
|
|
26.
Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant
H. Activation of innate immune responses through Toll-like
receptor 3 causes a rapid loss of salivary gland function. J
Oral Pathol Med. 2009;38:42-7.
https://doi.org/10.1111/j.1600-0714.2008.00700.x
PMid:19192049 PMCid:PMC2763314
|
|
|
|
|
27. Li R, Xie J, Kantor C, Koistinen
V, Altieri DC, Nortamo P, et al. A peptide derived from the
intercellular adhesion molecule-2 regulates the avidity of the
leukocyte integrins CD11b/CD18 and CD11c/CD18. J
Cell Biol. 1995;129:1143-53.
https://doi.org/10.1083/jcb.129.4.1143
PMid:7744962
|
|
|
|
|
28. Garcia-Carrasco M,
Fuentes-Alexandro S, Escarcega RO, Salgado G, Riebeling C,
Cervera R. Pathophysiology of Sjogren's syndrome. Arch Med Res.
2006;37:921-32.
https://doi.org/10.1016/j.arcmed.2006.08.002
PMid:17045106
|
|
|
|
|
29. Mitsias DI, Tzioufas AG,
Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, et al. The Th1/Th2 cytokine balance changes
with the progress of the immunopathological lesion of Sjogren's
syndrome. Clin Exp Immunol. 2002;128:562-8.
https://doi.org/10.1046/j.1365-2249.2002.01869.x
PMid:12067313 PMCid:PMC1906267
|
|
|
|
|
30.
Daridon C, Devauchelle V, Hutin P, Berre RL, Martins-Carvalho
C, Bendaoud B, et al. Aberrant expression of BAFF by B
lymphocytes infiltrating the salivary glands of patients with
primary Sjögren's syndrome. Arthritis &
Rheumatism. 2007;56:1134-44.
https://doi.org/10.1002/art.22458
PMid:17393395
|
|
|
|
|
31.
Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider
P, et al. Association of BAFF/BLyS overexpression and altered B
cell differentiation with Sjogren's syndrome. J Clin Invest.
2002;109:59-68.
https://doi.org/10.1172/JCI0214121
PMid:11781351 PMCid:PMC150825
|
|
|
|
|
32.
Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J,
et al. BAFF mediates survival of peripheral immature B lymphocytes.
J Exp Med. 2000;192:1453-66.
https://doi.org/10.1084/jem.192.10.1453
PMid:11085747 PMCid:PMC2193190
|
|
|
|
|
33.
Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M,
Schneider P, et al. Mice transgenic for BAFF develop
lymphocytic disorders along with autoimmune manifestations. J
Exp Med. 1999;190:1697-710.
https://doi.org/10.1084/jem.190.11.1697
PMid:10587360 PMCid:PMC2195729
|
|
|
|
|
34.
Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K.
Association between circulating levels of the novel TNF family
members APRIL and BAFF and lymphoid organization in primary
Sjogren's syndrome. J Clin Immunol. 2005;25:189-201.
https://doi.org/10.1007/s10875-005-4091-5
PMid:15981083
|
|
|
|
|
35.
Thorn M, Lewis RH, Mumbey-Wafula A, Kantrowitz S, Spatz LA.
BAFF overexpression promotes anti-dsDNA B-cell maturation and
antibody secretion. Cell Immunol. 2010;261:9-22.
https://doi.org/10.1016/j.cellimm.2009.10.004
PMid:19914608 PMCid:PMC2812582
|
|
|
|
|
36.
Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et
al. The level of BLyS (BAFF) correlates with the titre of
autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003;62:168-71.
https://doi.org/10.1136/ard.62.2.168
PMid:12525388 PMCid:PMC1754442
|
|
|
|
|
37.
Lipsky PE. Systemic lupus erythematosus: an autoimmune disease
of B cell hyperactivity. Nature immunology.
2001;2:764-6.
https://doi.org/10.1038/ni0901-764
PMid:11526379
|
|
|
|
|
38.
Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et
al. Biologic activity and safety of belimumab, a neutralizing
anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a
phase I trial in patients with systemic lupus erythematosus.
Arthritis Res Ther. 2008;10:R109.
https://doi.org/10.1186/ar2506
PMid:18786258 PMCid:PMC2592791
|
|
|
|
|
39.
Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M,
Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin
levels after atacicept treatment in patients with systemic
lupus erythematosus: results of a multicenter, phase Ib,
double-blind, placebo-controlled, dose-escalating trial. Arthritis
Rheum. 2007;56:4142-50.
https://doi.org/10.1002/art.23047
PMid:18050206
|
|
|
|
|
40.
Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K, Sa S,
et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral
blood B cells and lymphoid tissue marginal zone and follicular
B cells in cynomolgus monkeys. Am J Pathol. 2006;168:476-89.
https://doi.org/10.2353/ajpath.2006.050600
PMid:16436662 PMCid:PMC1606502
|
|
|
|
|
41.
Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K,
Takasaki Y. Anti-Ro/SSA antibodies are an independent factor
associated with an insufficient response to tumor necrosis
factor inhibitors in patients with rheumatoid arthritis. J
Rheumatol. 2011;38:2346-54.
https://doi.org/10.3899/jrheum.101295
PMid:21965648
|
|
|
|
|
42. Espinosa A, Hennig J, Ambrosi A,
Anandapadmanaban M, Abelius MS, Sheng Y, et al. Anti-Ro52 autoantibodies from patients
with Sjogren's syndrome inhibit the Ro52 E3 ligase activity by
blocking the E3/E2 interface. J Biol Chem. 2011;286:36478-91.
https://doi.org/10.1074/jbc.M111.241786
PMid:21862588 PMCid:PMC3196112
|
|
|
|
|
43.
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R,
et al. Depletion of B cells in vivo by a chimeric mouse human
monoclonal antibody to CD20. Blood. 1994;83:435-45.
PMid:7506951
|
|
|
|
|
44. Pijpe J, van Imhoff GW,
Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with
primary Sjogren's syndrome: an open-label phase II study. Arthritis
Rheum. 2005;52:2740-50.
https://doi.org/10.1002/art.21260
PMid:16142737
|
|
|
|
|
45. Skopouli FN, Jagiello P,
Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjogren's
syndrome. Clin
Exp Rheumatol. 1996;14:555-8.
PMid:8913659
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|